Hepatoxicity in an African HIV Treatment Cohort

非洲艾滋病毒治疗队列中的肝毒性

• 批准号: 7064596
• 负责人: CHRISTOPHER J HOFFMANN
• 金额: $ 5.79万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-01 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7064596
• 关键词: Africa; African; American; HAART (highly active antiretroviral therapy); HIV infections; United States; alcoholic beverage consumption; alternative medicine; chronic disease /disorder; clinical research; comorbidity; disease /disorder proneness /risk; drug adverse effect; geographic difference; hepatotoxin; human subject; infection; infectious hepatitis; international cooperation; interview; liver toxic disorder; medical complication; microorganism disease chemotherapy; postdoctoral investigator; serology /serodiagnosis; tuberculosis

DESCRIPTION (provided by applicant): Use of antiretroviral (ARV) therapy to suppress HIV and allow immune reconstitution has shifted mortality from opportunistic infections to complications of chronic infections and ARV therapy. A significant and potentially fatal adverse effect is hepatotoxicity. Recent rapid expansion of ARV therapy in developing countries has the potential to reverse the AIDS mortality currently devastating these areas but drug toxicity may present a barrier to program success. One known risk factor for hepatotoxicity, hepatitis B (HBV), is hyper-endemic in parts of Africa. In addition to HBV, multiple other known and potential risks for hepatotoxicity may exist including alcohol, traditional medicines, and tropical diseases. We propose to test the hypothesis that the incidence of ARV-related hepatotoxicity is greater in Africa than in North America and that risk factors differ. This study will measure incidence of hepatotoxicity in an African ARV therapy cohort and identify risks for hepatotoxicity by matching cases with controls and testing banked serum and a administering a structured interview. It will be conducted within a large and on-going ARV cohort established as a collaborative project between a South African industrial conglomerate and Johns Hopkins University.

描述（由申请人提供）：使用抗逆转录病毒（ARV）疗法抑制艾滋病毒并允许免疫结构造成，使死亡率从机会性感染转变为慢性感染和ARV治疗的并发症。肝毒性是一种显着且潜在的致命不利影响。发展中国家ARV治疗的最近快速扩张有可能扭转目前破坏这些地区的艾滋病死亡率，但药物毒性可能会带来计划成功的障碍。在非洲部分地区，肝炎B（HBV）的肝炎B（HBV）是一个已知的危险因素。除HBV外，还可能存在多种其他已知和潜在的肝毒性风险，包括酒精，传统药物和热带疾病。我们建议检验以下假设：非洲与​​ARV相关的肝毒性的发病率大于北美，并且危险因素有所不同。这项研究将在非洲ARV疗法队列中衡量肝毒性的发生率，并通过将病例与对照组合和测试库的血清和管理结构化访谈进行匹配，从而确定肝毒性的风险。它将在一个大型且持续的ARV队列中进行，该队列是南非工业集团和约翰·霍普金斯大学之间的合作项目。